Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model

Cancer Immunology Research

Volumn 4, Issue 2, 2016, Pages 124-135

  Reardon, David A ^a   Gokhale, Prafulla C ^a   Klein, Sarah R ^a   Ligon, Keith L ^a   Rodig, Scott J ^a   Ramkissoon, Shakti H ^a   Jones, Kristen L ^a   Conway, Amy Saur ^a   Liao, Xiaoyun ^a   Zhou, Jun ^a   Wen, Patrick Y ^a   Van Den Abbeele, Annick D ^a,b   Hodi, F Stephen ^a   Qin, Lei ^a   Kohl, Nancy E ^a   Sharpe, Arlene H ^c   Dranoff, Glenn ^a   Freeman, Gordon J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CCL6 CHEMOKINE; CCL9 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EOTAXIN; PROGRAMMED DEATH 1; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 2; PROTEIN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ERADICATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; INTRACRANIAL TUMOR; LONG TERM SURVIVAL; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DISEASE MODEL; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR RECURRENCE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; GLIOBLASTOMA; IMMUNITY; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR BURDEN;

EID: 84962032646     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0151     Document Type: Article

References (22)

1. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
2. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
3. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100-8.
4. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015;523:337-41.
5. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res 2014;20:5620-9.
6. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2015;17:1064-75.
7. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, et al. PD-L1 and PD-L2modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol 2010;3:81-91.
8. Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 2011;60:153-60.
9. Peng Y, Luo G, Zhou J, Wang X, Hu J, Cui Y, et al. CD86 is an activation receptor for NK cell cytotoxicity against tumor cells. PLoS One 2013;8:e83913.
10. Hanna J, Fitchett J, Rowe T, Daniels M, Heller M, Gonen-Gross T, et al. Proteomic analysis of human natural killer cells: insights on new potential NK immune functions. Mol Immunol 2005;42:425-31.
11. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathwaysto reverseTcellexhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187-94.
12. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
13. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014;2:846-56.
14. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007;13:2158-67.
15. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012;18:6110-21.
16. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343-9.
17. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT, Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 2012;35:385-9.
18. Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, et al. Intratumoral IL-12 combined with CTLA-4blockade elicitsTcell-mediated glioma rejection. J Exp Med 2013;210:2803-11.
19. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014;9:e101764.
20. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20:5290-301.
21. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
22. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2015;17:1064-75.